Success Metrics

Clinical Success Rate
38.5%

Based on 5 completed trials

Completion Rate
38%(5/13)
Active Trials
0(0%)
Results Posted
180%(9 trials)
Terminated
8(57%)

Phase Distribution

Ph phase_3
1
7%
Ph phase_1
12
86%
Ph phase_2
1
7%

Phase Distribution

12

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
12(85.7%)
Phase 2Efficacy & side effects
1(7.1%)
Phase 3Large-scale testing
1(7.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

35.7%

5 of 14 finished

Non-Completion Rate

64.3%

9 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(5)
Terminated(9)

Detailed Status

Terminated8
Completed5
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
38.5%
Most Advanced
Phase 3

Trials by Phase

Phase 112 (85.7%)
Phase 21 (7.1%)
Phase 31 (7.1%)

Trials by Status

withdrawn17%
completed536%
terminated857%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT04029688Phase 1

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Terminated
NCT02633059Phase 1

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed
NCT05952687Phase 1

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

Withdrawn
NCT03555149Phase 1

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Terminated
NCT03158389Phase 1

NCT Neuro Master Match - N²M² (NOA-20)

Completed
NCT03850535Phase 1

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Terminated
NCT02545283Phase 3

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated
NCT02670044Phase 1

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Completed
NCT03287245Phase 2

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Terminated
NCT03135262Phase 1

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated
NCT03566485Phase 1

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Terminated
NCT02624986Phase 1

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Terminated
NCT03362723Phase 1

A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors

Completed
NCT02828930Phase 1

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14